VRVIX | VVIAX | VRVIX / VVIAX | |
Total Expense Ratio | 0.06 | 0.05 | 120% |
Annual Report Gross Expense Ratio | 0.06 | 0.05 | 120% |
Fund Existence | 14 years | 24 years | - |
Gain YTD | -2.464 | -2.638 | 93% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 5000000 | 3000 | 166,667% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 12.9B | 191B | 7% |
Annual Yield % from dividends | 2.00 | 2.26 | 89% |
Returns for 1 year | 4.30 | 4.43 | 97% |
Returns for 3 years | 14.03 | 15.65 | 90% |
Returns for 5 years | 69.34 | 71.29 | 97% |
Returns for 10 years | 73.08 | 92.76 | 79% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BIS | 19.06 | 0.54 | +2.92% |
ProShares UltraShort Nasdaq Biotech | |||
NOCT | 49.87 | 0.28 | +0.57% |
Innovator Growth-100 Pwr Buff ETF™ Oct | |||
SIXA | 45.94 | 0.03 | +0.07% |
ETC 6 Meridian Mega Cap Equity ETF | |||
FEUZ | 48.61 | N/A | N/A |
First Trust Eurozone AlphaDEX® ETF | |||
SIVR | 31.50 | -0.54 | -1.69% |
abrdn Physical Silver Shares ETF |